NEW YORK, NY—A systematic program designed to close the diagnosis and treatment gaps for patients with aortic stenosis (AS) ...

Edwards TAVR data has a strong showing at NY Valves 2026 amid intense industry competition from Abbott Laboratories and Medtronic.

While the dataset is incomplete, the death and stroke curves appear to separate at 2 years, notes Philippe Généreux.

Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...

BACKGROUND: Undertreatment and delayed treatment of aortic stenosis (AS) are common, both of which are associated with increased mortality. Historically, assessment of quality for AS care has focused ...

Results of care registry released with new TAVR national coverage determination on the hor ...

New research simultaneously published today in JSCAI and presented at New York Valves 2026 reported favorable one-year ...

Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the ...

New research published in JSCAI and presented at New York Valves 2026 reports favorable one-year outcomes in patients with symptomatic severe aortic regurgitation following treatment with the ...

The FDA cleared EchoNext, the first artificial intelligence tool to detect structural heart disease before symptoms present.

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Different breeds of dog have very different chances of living largely illness-free lives.